Lixivaptan in a Single Subject With Intractable Pain Due to Polycystic

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

Abdominal pain, sometimes severe, is a known symptom of polycystic kidney disease (PKD) related to the cystic expansion. This study will investigate whether the vasopressin V2 receptor antagonist lixivaptan can alleviate intractable pain in a pediatric PKD patient who cannot tolerate the related vasopressin V2 receptor antagonist tolvaptan.

See also
Status	Clinical Trial	Phase
Terminated	`NCT00801268` - Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease	N/A
Completed	`NCT00491517` - Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety	Phase 2
Recruiting	`NCT05286632` - KidneYou - Innovative Digital Therapy	N/A
Active, not recruiting	`NCT00771888` - Open-Label Extension of LOCKCYST Trial	Phase 2/Phase 3

NCT number	NCT03717181
Study type	Expanded Access
Source	Palladio Biosciences
Contact
Status	No longer available
Phase

Lixivaptan in a Single Subject With Intractable Pain Due to Polycystic Kidney Disease

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms